Genenta Science Net Worth
Genenta Science Net Worth Breakdown | GNTA |
Genenta Science Net Worth Analysis
Genenta Science's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Genenta Science's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Genenta Science's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Genenta Science's net worth analysis. One common approach is to calculate Genenta Science's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Genenta Science's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Genenta Science's net worth. This approach calculates the present value of Genenta Science's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Genenta Science's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Genenta Science's net worth. This involves comparing Genenta Science's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Genenta Science's net worth relative to its peers.
Enterprise Value |
|
To determine if Genenta Science is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genenta Science's net worth research are outlined below:
| Genenta Science SpA had very high historical volatility over the last 90 days | |
| Net Loss for the year was (8.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Genenta Science SpA currently holds about 37.24 M in cash with (6.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.04. | |
| Genenta Science SpA has a poor financial position based on the latest SEC disclosures | |
| Roughly 39.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BCML Stock Analysis and Forecast - Consistently exceptional gains - jammulinksnews.com |
Genenta Science uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genenta Science SpA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genenta Science's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 24th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 24th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Genenta Science Target Price Consensus
Genenta target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Genenta Science's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Genenta analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Genenta stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Genenta Science SpA, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGenenta Science Target Price Projection
Genenta Science's current and average target prices are 3.86 and 27.29, respectively. The current price of Genenta Science is the price at which Genenta Science SpA is currently trading. On the other hand, Genenta Science's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Genenta Science Market Quote on 31st of July 2025
Target Price
Analyst Consensus On Genenta Science Target Price
Know Genenta Science's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genenta Science is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genenta Science SpA backward and forwards among themselves. Genenta Science's institutional investor refers to the entity that pools money to purchase Genenta Science's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Allianz Se | 2025-03-31 | 233.6 K | Alti Global Inc | 2025-03-31 | 200.3 K | Algebris Investment Management (uk) Llp | 2025-03-31 | 100 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 3.4 K | Ubs Group Ag | 2025-03-31 | 91.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 |
Follow Genenta Science's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 67.71 M.Market Cap |
|
Project Genenta Science's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.65) | (0.69) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (0.66) | (0.62) |
When accessing Genenta Science's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Genenta Science's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genenta Science's profitability and make more informed investment decisions.
Please note, the presentation of Genenta Science's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genenta Science's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genenta Science's management manipulating its earnings.
Evaluate Genenta Science's management efficiency
Genenta Science SpA has return on total asset (ROA) of (0.3284) % which means that it has lost $0.3284 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5413) %, meaning that it created substantial loss on money invested by shareholders. Genenta Science's management efficiency ratios could be used to measure how well Genenta Science manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.57. In addition to that, Return On Capital Employed is expected to decline to -0.69. At present, Genenta Science's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 19.1 M, whereas Net Tangible Assets are forecasted to decline to about 13.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.01 | 1.10 | |
| Tangible Asset Value | 28 M | 24.9 M | |
| Tangible Book Value Per Share | 1.01 | 1.10 | |
| Enterprise Value Over EBITDA | (6.00) | (6.30) | |
| Price Book Value Ratio | 4.59 | 6.97 | |
| Enterprise Value Multiple | (6.00) | (6.30) | |
| Price Fair Value | 4.59 | 6.97 | |
| Enterprise Value | 89.6 M | 128.7 M |
Understanding the operational decisions made by Genenta Science management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genenta Science insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genenta Science's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genenta Science insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Rosenwald Lindsay A Md over six months ago Disposition of 506245 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Driscoll Martin J over six months ago Acquisition by Driscoll Martin J of 4999 shares of Genenta Science at 0.25 subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over a year ago Disposition of 64562 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 | ||
Rosenwald Lindsay A Md over a year ago Disposition of 2287 shares by Rosenwald Lindsay A Md of Genenta Science subject to Rule 16b-3 |
Genenta Science Earnings per Share Projection vs Actual
Genenta Science Corporate Management
| Carlo MD | Chief Development | Profile | |
| Richard Slansky | Chief Officer | Profile | |
| Tim Obara | Head Devel | Profile | |
| Luigi MD | CoFounder Board | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genenta Science SpA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genenta Science. If investors know Genenta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genenta Science listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Genenta Science SpA is measured differently than its book value, which is the value of Genenta that is recorded on the company's balance sheet. Investors also form their own opinion of Genenta Science's value that differs from its market value or its book value, called intrinsic value, which is Genenta Science's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genenta Science's market value can be influenced by many factors that don't directly affect Genenta Science's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genenta Science's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genenta Science is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genenta Science's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.